New York, NY (PRWEB) May 20, 2013
Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit on behalf of a South Dakota man who alleges that use of the diabetes drug medication Actos (pioglitazone) caused bladder cancer. The suit was filed on April 30, 2013, in the U.S. District Court for the Western District of Louisiana (Case No. 6:13-cv-0888), where it is one of thousands of cases pending in the Actos multidistrict litigation (In Re: Actos (Pioglitazone) Products Liability Litigation, MDL No. 6:11-md-2299). Jerrold S. Parker, founding partner of Parker Waichman LLP, serves on the Plaintiffs’ Steering Committee in the litigation. Takeda Pharmaceuticals, America; Takeda Pharmaceuticals USA, Inc. f/k/a Takeda Pharmaceuticals North America, Inc.; Takeda Pharmaceutical Company Limited; and Eli Lilly and Company have been named as Defendants.
According to the Complaint, the Plaintiff began taking Actos in January 2009. He developed bladder cancer in May 2011, allegedly due to the side effects of Actos. At this time, he stopped taking the medication. The lawsuit alleges that the Defendants were aware that taking the diabetes drug could lead to an increased risk of bladder cancer, but failed to disclose this information to the Plaintiff, his doctor and other consumers. The Plaintiff is suing for extensive pain and suffering, severe emotional distress.
According to the U.S. Food and Drug Administration (FDA), taking Actos for one year may significantly increase your risk of bladder cancer. The safety label for Actos was updated in June 2011 to reflect this risk*. The warning was based on the results of an ongoing 10-year study by Kaiser Permanente. *(http://www.f
Copyright©2012 Vocus, Inc.
All rights reserved